VERU News and Press, Veru Inc. From 04/20/23

2023-04-20 11:26:14 ET If you’re looking for the best penny stocks to buy right now, news headlines may be a good place to look. While there’s no guarantee that good news will be “good” for a stock, more times than not, it can act as an immediate catalyst. Th...

2023-04-20 06:55:50 ET Veru ( NASDAQ: VERU ) shares jumped 6% premarket on Thursday after the biopharmaceutical company announced the sale of its ENTADFI (finasteride and tadalafil) capsules business for benign prostatic hyperplasia. Blue Water Vaccines ( NASDAQ: BWV ...

MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced the sale of its ENTADFI ® (finasteride and tadalafil) capsules busi...

2023-04-19 09:41:08 ET Veru ( NASDAQ: VERU ) said it signed a supply agreement with Afaxys Group Services (AGS) to offer its FC2 Female Condom (internal condom) through the AGS Group Purchasing Organization (GPO). Under the agreement, Afaxys members will have access to a ...

MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases that has a commercial sexual health division, today announced it has entered into a Purchasin...

2023-04-11 10:13:50 ET Veru ( NASDAQ: VERU ) said a preclinical study showed that its drug, sabizabulin, to treat prototypical poxvirus, vaccinia virus prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. ( VERU ...

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Investigational New Drug (IND) meeting with FDA to...

2023-04-04 09:17:24 ET Veru ( NASDAQ: VERU ) shares added ~7% pre-market Tuesday after disclosing that the FDA has granted a meeting to discuss a Phase 3 confirmatory study for sabizabulin, the company’s experimental COVID-19 therapy. In early March, the FDA declined ...

In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive Phase 3 COVID-19 clinical study and preclinical influenza study further support the potential u...

2023-03-14 16:23:10 ET Despite an FDA decision to reject its experimental oral COVID therapy sabizabulin early this month, Veru ( NASDAQ: VERU ) announced Tuesday it would continue to proceed with its studies targeting infectious diseases, including COVID-19. Citing remark...